<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059783</url>
  </required_header>
  <id_info>
    <org_study_id>20984</org_study_id>
    <nct_id>NCT04059783</nct_id>
  </id_info>
  <brief_title>Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function</brief_title>
  <official_title>Non-interventional Study on the Onset of Effect of Iberogast in Patients With Functional or Motility-related Gastrointestinal Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have been done on the efficacy of the herbal medicine Iberogast. In this
      study researcher want to learn more about the time needed for Iberogast to start to work
      after the patient took the drug. This study plans to enroll 300 adult male and female
      patients suffering from disturbance of stomach and intestine normal function and treated by
      their doctor with Iberogast drops. Patients will be asked to document on a diary card the
      changes of symptom severity of the stomach and intestine complaints and the time needed for
      the symptoms to improve after drug intake. At the end of the study the treating doctor and
      the patients will be asked about the overall changes of symptoms. In addition information on
      the safety of the drug and how well the drug is tolerated by the patients will be collected
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 17, 2008</start_date>
  <completion_date type="Actual">February 20, 2011</completion_date>
  <primary_completion_date type="Actual">April 27, 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of GIS score from baseline up to 3 weeks after treatment</measure>
    <time_frame>At baseline and up to 3 weeks post-treatment</time_frame>
    <description>Gastrointestinal System Profile (GIS) includes 5 scores: 0=Not available, 1=Slight, 2=Moderate, 3=Severe, 4=Very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global assessment by the physicians using a 4-point likert scale</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Therapeutic success assessed by physicians. 0=Not improved, 1=Slightly improved, 2=Significantly approved, 3=No symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global assessment by the patient using a 4-point likert scale</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Therapeutic success assessed by patient. 0=Not improved, 1=Slightly improved, 2=Significantly approved, 3=No symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of ratings of symptom severity on a 100-mm visual analogue scale (VAS) over time after intake of Iberogast</measure>
    <time_frame>At baseline and up to 2 hours post-treatment on day 1</time_frame>
    <description>Visual Analogue Scale to evaluate the general severity of symptoms. It is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no symptoms) to 100 mm (severe symptoms).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of improvement assessed by patient on day 1</measure>
    <time_frame>On day 1</time_frame>
    <description>The onset of effect (severity of the functional gastrointestinal symptoms as well as the time frame within which the symptoms improved) was documented by the patients in the patient diary card. According to the time frame stated in the card (1 minute, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, more than 2 hours), the patients had to mark the time with a cross at which their symptoms significantly improved (i.e. perceived by the patient) following the one-time intake of Iberogast at morning, noon and evening on day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of improvement assessed by patient on day 2</measure>
    <time_frame>On day 2</time_frame>
    <description>The onset of effect (severity of the functional gastrointestinal symptoms as well as the time frame within which the symptoms improved) was documented by the patients in the patient diary card. According to the time frame stated in the card (1 minute, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, more than 2 hours), the patients had to mark the time with a cross at which their symptoms significantly improved (i.e. perceived by the patient) following the one-time intake of Iberogast at morning, noon and evening on day 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of improvement assessed by patient on day 3</measure>
    <time_frame>On day 3</time_frame>
    <description>The onset of effect (severity of the functional gastrointestinal symptoms as well as the time frame within which the symptoms improved) was documented by the patients in the patient diary card. According to the time frame stated in the card (1 minute, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, more than 2 hours), the patients had to mark the time with a cross at which their symptoms significantly improved (i.e. perceived by the patient) following the one-time intake of Iberogast at morning, noon and evening on day 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of improvement assessed by patient on day 4</measure>
    <time_frame>On day 4</time_frame>
    <description>The onset of effect (severity of the functional gastrointestinal symptoms as well as the time frame within which the symptoms improved) was documented by the patients in the patient diary card. According to the time frame stated in the card (1 minute, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, more than 2 hours), the patients had to mark the time with a cross at which their symptoms significantly improved (i.e. perceived by the patient) following the one-time intake of Iberogast at morning, noon and evening on day 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of improvement assessed by patient on day 5</measure>
    <time_frame>On day 5</time_frame>
    <description>The onset of effect (severity of the functional gastrointestinal symptoms as well as the time frame within which the symptoms improved) was documented by the patients in the patient diary card. According to the time frame stated in the card (1 minute, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, more than 2 hours), the patients had to mark the time with a cross at which their symptoms significantly improved (i.e. perceived by the patient) following the one-time intake of Iberogast at morning, noon and evening on day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of improvement assessed by patient on day 6</measure>
    <time_frame>On day 6</time_frame>
    <description>The onset of effect (severity of the functional gastrointestinal symptoms as well as the time frame within which the symptoms improved) was documented by the patients in the patient diary card. According to the time frame stated in the card (1 minute, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, more than 2 hours), the patients had to mark the time with a cross at which their symptoms significantly improved (i.e. perceived by the patient) following the one-time intake of Iberogast at morning, noon and evening on day 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of improvement assessed by patient on day 7</measure>
    <time_frame>On day 7</time_frame>
    <description>The onset of effect (severity of the functional gastrointestinal symptoms as well as the time frame within which the symptoms improved) was documented by the patients in the patient diary card. According to the time frame stated in the card (1 minute, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, more than 2 hours), the patients had to mark the time with a cross at which their symptoms significantly improved (i.e. perceived by the patient) following the one-time intake of Iberogast at morning, noon and evening on day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of improvement assessed by patient on day 8</measure>
    <time_frame>On day 8</time_frame>
    <description>The onset of effect (severity of the functional gastrointestinal symptoms as well as the time frame within which the symptoms improved) was documented by the patients in the patient diary card. According to the time frame stated in the card (1 minute, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, more than 2 hours), the patients had to mark the time with a cross at which their symptoms significantly improved (i.e. perceived by the patient) following the one-time intake of Iberogast at morning, noon and evening on day 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of participants with adverse events</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Participants who had adverse events during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants who discontinued from treatment</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Participants who discontinued from study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with the need of further treatment</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Participants who needed further treatment</description>
  </secondary_outcome>
  <enrollment type="Actual">272</enrollment>
  <condition>Functional Gastrointestinal Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STW5 (IberogastÂ®, BAY98-7411)</intervention_name>
    <description>The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients of at least 18 years were to be observed
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        At the discretion of physician under the instructions of Rome III criteria concerning
        functional gastrointestinal symptoms as well as the summary of product characteristics of
        Iberogast

        Exclusion criteria:

        Therapeutic necessity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Many locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

